# TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

> **NCT01052883** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 32 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- **DRUG:** DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- **DRUG:** DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
- **DRUG:** DRV commercial formulation/ DRV new formulation/ rtv 100mg tab

## Key facts

- **NCT ID:** NCT01052883
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01052883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01052883, "TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01052883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*